It was demonstrated that PAH patients, who are carriers of BMPR2 mutations, are younger at diagnosis, with a higher mean PA pressure and pulmonary vascular resistance, being less likely to respond to acute vasodilator testing than the other patients. Here, BMPR2 is linked to pulmonary arterial hypertension.